Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer

Submitted: 29 August 2019
Accepted: 25 November 2019
Published: 11 December 2019
Abstract Views: 1256
PDF: 864
HTML: 6
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Serine-arginine protein kinase (SRPK) belongs to a class of cell cycle regulating kinases that can phosphorylate proteins containing serine/arginine-Rich (SR) regions. SR proteins are a family of RNA binding phosphoproteins that control both constitutive and alternative pre-mRNA splicing events. However, little is known about their role in non-small cell lung cancer (NSCLC). In the present study, we found that serine-arginine protein kinase 2 (SRPK2) expression was upregulated in NSCLC tissues compared with adjacent normal tissues. Kaplan-Meier curve analyses showed that the overall survival time of NSCLC patients with high SRPK2 expression was shorter than those with low SRPK2 expression. Overexpression of SRPK2 promoted NSCLC cell proliferation and cell cycle arrest, while knockdown of SRPK2 inhibited proliferation and promoted cell cycle arrest in NSCLC cell lines. SRPK2 promoted the transcriptional regulation of E2F1 on downstream cell cycle related genes through phosphorylation of SC35. Xenograft model showed that SRPK2 promoted tumor growth in vivo. SRPK2 phosphorylated SC35 and phosphorylated SC35 activated E2F1 transcription of cyclin-related proteins, thereby promoting the cycle progression of NSCLC. Our findings demonstrated that SRPK2 may be a potential therapeutic target for NSCLC clinical therapy, which plays an important role in the progression of NSCLC. 

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Ethics Approval

Ethics Committee of First Affiliated Hospital of Shantou University Medical College, Written informed consent: obtained

How to Cite

Li, X., Yang, S., Zhang, M. ., Xie, S. ., & Xie, Z. (2019). Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer. European Journal of Histochemistry, 63(4). https://doi.org/10.4081/ejh.2019.3067